Dinaciclib, a pan-CDK inhibitor, has been shown to downregulate MCL1 leading to apoptosis induction and antitumor efficacy in DLBCL preclinical models (25) and clinical activity has been demonstrated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL; ref. 26). Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.